The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to investigate a complaint against Otsuka. The HJI has reported that the company is alleged to be engaging in exclusionary practices for the drug Delamanid. A hearing for the complaint has not been scheduled with the tribunal at this time.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
80
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
30
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
450
bottom of page
Comments